23andMe Investor Presentation Deck

CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe's Proprietary Immuno-oncology (I/O) Genetic Signature Immune and autoimmune phenotypes Cancer phenotypes Identified novel immuno-oncology signature around CTLA4. tonsillectomy- 110- anli Int alpha or dards juvenile 11d- iqb dry skin frequency- iodine treatment ever- hypothyroidism hyperthyroidism hashimotos- graves- vitiligo- iqb dandruft frequency- celiac HLA all- psoriasis- rheumatoid arthritis- took meds anti tnf alpha- thymid_removed- immunodeficiency- squamous call carcinoma- basal cell carcinoma- actinic keratosis- non melanoma skin cancer- any skin cancer- signed log(p) -100 510 Genetic Variant in CTLA4 linked with multiple phenotypes in the 23andMe database CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature CD200R1 Receptor թսոաալ I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes Cancer Cancer Immune CD200 Ligand DOK2 Protein Immune Cancer signed log(p) -10 -5 0 5 10 We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs Copyright © 2022 23and Me, Inc. 23and Me 39

View entire presentation